Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | CASP1 | P29466 | 4/20 | 0.66 |
| ▸ | CASP7 | P55210 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23278846 | 0.94 | ADORA3 (0.72) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL23483932 | 0.94 | ADORA3 (0.69) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| Kaempferol Tetraacetate SCHEMBL10379364 | 0.91 | ADORA3 (0.84) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL20581611 | 0.89 | ADORA3 (0.78) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL15965556 | 0.88 | KDM4E (0.66) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL22529297 | 0.88 | ADORA3 (0.61) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL21819719 | 0.87 | ADORA3 (0.72) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL1664667 | 0.87 | ADORA3 (1.00) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL10429428 | 0.85 | ABCG2 (0.77) | ADORA3KDM4ECYP3A4HSD17B10MAPT | |
| SCHEMBL5132499 | 0.85 | ADORA3 (0.57) | ADORA3KDM4ECYP3A4HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2009-05-21 | — | — | US | claimed |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-7863323-B1 | Flavonols | THE UNIVERSITY OF MELBOURNE (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863323-B1 | Flavonols | THE UNIVERSITY OF MELBOURNE (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863323-B1 | Flavonols | THE UNIVERSITY OF MELBOURNE (AU) | 2011-01-04 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| JP-2009096731-A | CARBOXYMETHYL ARGININE PRODUCTION INHIBITOR | KUMAMOTO UNIV | 2009-05-07 | — | — | JP | disclosed |
| WO-2002020834-A2 | METHOD FOR THE IDENTIFICATION OF GENES THAT ARE INVOLVED IN THE MODULATION OF A POPTOSIS IN CELLS | EIRX THERAPEUTICS LIMITED (IE) | 2002-03-14 | — | — | WO | disclosed |
| US-6258840-B1 | ANTITUMOR AGENTS, ANTIINFLAMMATORY AGENTS, ENZYME INHIBITORS OF KINASES | COBRA THERAPEUTICS LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| EP-0912541-A1 | ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) | Cobra Therapeutics Limited (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997049693-A1 | ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) | COBRA THERAPEUTICS LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | ADORA3 2284/4885KDM4E 4251/4885CYP3A4 1385/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | ADORA3 1365/4885KDM4E 558/4885CYP3A4 1055/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | ADORA3 2284/4885KDM4E 4251/4885CYP3A4 1385/4885 |
| US-20090130051-A1 | Flavonoid Compounds and Uses Thereof | CAT, NQO1, GPX4 | ADORA3 2776/4885KDM4E 4144/4885CYP3A4 518/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | ADORA3 3910/4885KDM4E 2438/4885CYP3A4 2661/4885 |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | ENPP2, MBOAT7, AADAC | ADORA3 3697/4885KDM4E 2430/4885CYP3A4 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.